Bevacizumab beyond disease progression for advanced non–small cell lung cancer: Does persistence have its rewards?
Persistence pays off when it comes to the vascular endothelial growth factor inhibitor bevacizumab in non–small cell lung cancer patients who have progressed on first‐line chemotherapy. Continued vascular endothelial growth factor blockade after progression on first‐line therapy may provide at least...
Saved in:
Published in: | Cancer Vol. 122; no. 7; pp. 1047 - 1049 |
---|---|
Main Authors: | , , |
Format: | Journal Article |
Language: | English |
Published: |
United States
01-04-2016
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!